Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma

Subjects with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing HCC
surveillance will be enrolled and have blood samples collected. Subjects undergoing HCC
surveillance will be followed for up to 6 months. Another blood sample will be collected at
the 6 month visit which will be scheduled no longer than 6 months from enrollment.

Inclusion Criteria:

- All Subjects:

1. Subject is 18 years of age or older

2. Subject understands the study procedures and is able to provide informed consent
to participate in the study and authorization for release of data, including
personal health data, to the study investigator and sponsor

HCC Subjects:

1. Subject has a recent (within 6 months of enrollment) untreated clinically diagnosed
hepatocellular carcinoma as defined by ≥1 cm lesion exhibiting arterial phase
hyperenhancement in combination with washout appearance and/or capsule by 4 phase CT scan
or multiphase contrast enhanced MRI or biopsy is positive for HCC.

Control Subjects:

1. Non-cancer subject undergoing routine imaging surveillance for HCC

2. Definitive lack of HCC within 3 months prior to enrollment as defined by negative
imaging, for HCC.

1. Control Group 1 - negative by ultrasound

2. Control Group 2 - negative by CT or MRI

Exclusion Criteria:

1. Known cancer diagnosis within the past 5 years (with the exceptions of basal cell or
squamous cell skin cancers).

2. Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample
collection.

3. Prior or current treatment with sorafenib, regorafenib, or other treatment indicated
for HCC.

4. Any HCC treatment prior to enrollment/blood sample collection (e.g., surgery,
ablation, embolization, pharmacotherapy, radiotherapy, liver transplant or other
treatment indicated for HCC).

5. IV contrast (e.g. CT and MRI) within 1 day [or 24 hours] of blood collection.

6. Less than 3 days between fine needle aspiration (FNA) of target pathology and blood
collection.

7. Less than 7 days between biopsy (other than FNA) of target pathology and blood
collection.

8. Individual has a condition the Investigator believes would interfere with his or her
ability to provide informed consent, comply with the study protocol, which might
confound the interpretation of the study results or put the person at undue risk.